An observational study in Congenital Ichthyosis, sponsored by Maastricht University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-11-08.
Sponsored by Maastricht University Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to learn about the presence of extracutaneous manifestations in patients with congenital ichthyosis.
The main question it aims to answer is:
Participants will fill in questionnaires in which the investigators will explore whether patients experience extracutaneous manifestations, and if so what these manifestations entail. Examples of such questions are whether patients experience (joint) pain or whether they experience hindrance due to their complaints.
There is only limited knowledge about extracutaneous manifestations in patients with congenital ichthyosis. With this study, the investigators aim to identify extracutaneous manifestations with questionaires based on patient reported outcomes.
Secondary research questions include:
Furthermore, the investigators aim to discover knowledge gaps in current patient management and possible areas of improvement in patient care towards healthcare professionals.
Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients 16 years and older, who have a clinically and genetically confirmed congenital ichthyosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Questionnaires
Other: Questionnaires with patient reported outcome measures
Questionnaires to gain insight of the prevalence of extracutaneous manifestations and the impact of the disease on the quality of life.
Extracutaneous manifestations in general
Evaluation of possible extracutaneous manifestations patients with congenital ichthyosis exhibit. This is measured by a questionnaire the investigators have composed. The questions entail patient reported outcomes on their general health and the health issues patients experience due to ichthyosis.
Time frame: Day 1
Prevalence of joint complaints measured by the Psoriasis Epidemiology Screening Tool
Prevalence of joint complaints measured by the Psoriasis Epidemiology Screening Tool (PEST). The higher the total score, the more joint complaints patients with congenital ichthyosis experience.
Time frame: Day 1
Prevalence of joint complaints measured by the Early Arthritis Recognition Clinic questionnaire
Prevalence of joint complaints measured by the Early Arthritis Recognition Clinic (EARC) questionnaire. The higher the total score, the more joint complaints patients with congenital ichthyosis experience.
Time frame: Day 1
Prevalence of joint complaints Early Arthritis for Psoriatic patients questionnaire
Prevalence of joint complaints measured by the Early Arthritis for Psoriatic patients (EARP) questionnaire. The higher the total score, the more joint complaints patients with congenital ichthyosis experience.
Time frame: Day 1
Prevalence of joint complaints measured by the Clinical Arthritis Rule questionnaire
Prevalence of joint complaints measured by the Clinical Arthritis Rule (CARE) questionnaire. The higher the total score, the more joint complaints patients with congenital ichthyosis experience.
Time frame: Day 1
Impact of ichthyosis on quality of life
Evaluation of quality of life measured by the Dermatology Life Quality Index (DLQI) questionnaire. Scores range from 0-30, where a higher score indicates that the skin disease has a bigger influence on their quality of life.
Time frame: Day 1
Impact of ichthyosis on quality of life measured by Skindex-29
Evaluation of the quality of life of patients with congenital ichthyosis measured by the Skindex-29 questionnaire. Scores ranging from \>25 and \>44, where a higher score indicates that the skin disease has a bigger influence on their quality of life.
Time frame: Day 1
Prevalence of itch complaints
Evaluation of possible extracutaneous manifestations patients with congenital ichthyosis exhibit. This is measured by a numeric rating scale (NRS) of itch. The higher the outcome, the more itch patients experience
Time frame: Day 1
Prevalence of pain complaints
Evaluation of possible extracutaneous manifestations patients with congenital ichthyosis exhibit. This is measured by a numeric rating scale (NRS) of pain. The higher the outcome, the more pain the patients experience
Time frame: Day 1
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Oct 2024, 13 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ichthyosis Vulgaris
Maastricht University Medical Center →